Inhaled Nitric Oxide Market Report by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others), and Region 2024-2032
세계의 흡입 일산화질소 시장 규모는 2023년 9억 4,370만 달러로 평가되었습니다. IMARC Group은 향후 시장이 2032년까지 16억 5,770만 달러에 이를 전망이며, 2024년부터 2032년까지 6.3%의 성장률(CAGR)을 보일 것으로 예측했습니다.
흡입 일산화질소(iNO)는 3차 신생아 집중 치료실(NICU)의 숙련된 의사가 감수하는 선택적 폐 혈관 확장제입니다. iNO는 환기와 관류의 불일치를 개선하고 폐 혈관 저항 상승과 고혈압을 줄임으로써 혈관 근육 긴장을 조절하고 신생아의 저산소성 호흡 부전을 치료하는 데 도움이 됩니다. 또한 산소화를 개선하고 체외막 산소 요법(ECMO)의 필요성을 줄이는 데 도움이 됩니다. 현재 급성 호흡 곤란 증후군(ARDS) 환자의 구호제로서 iNO 요법의 사용이 증가하고 있습니다.
흡입 일산화질소 시장 경향 :
지속성 폐 고혈압 및 신생아 저산소성 호흡 부전(HRF)과 같은 신생아의 호흡기 질환 및 기타 후속 질환의 유병률 증가는 시장 성장에 크게 기여하는 주요 요인 중 하나입니다. 또한, 고혈압, 아테롬성 동맥 경화증, 말초 동맥 질환, 심부전, 혈전증에 상대적으로 걸리기 쉬운 노인 인구 증가가 시장 성장을 지원합니다. 또한 iNO는 만성 폐색성 폐질환(COPD), 천식, ARDS의 치료를 위해 세계에서 절대적인 지지를 얻고 있습니다. 게다가 전염성이 높은 코로나바이러스병(COVID-19)의 발생과 세계 수준에서 감염자가 놀라울 정도로 증가하고 있는 것이 시장에 호영향을 주고 있습니다. 또한, iNO 요법은 중증 폐렴 환자의 환기 및 관류를 개선하는 데 도움이 되기 때문에 코로나바이러스 오염에 사용됩니다. 또한 전반적인 환자 경험을 향상시키기 위해 세계 건강 관리 산업에서 연구개발(R&D) 활동이 진행되고 있다는 점도 시장을 이끌고 있습니다.
이 보고서에서 다루는 주요 질문
- 세계의 흡입 일산화질소 시장은 지금까지 어떻게 추이하고 향후 어떻게 추이할 것인가?
- COVID-19는 세계의 흡입 일산화질소 시장에 어떤 영향을 미치는가?
- 주요 지역 시장은?
- 용도별 시장 내역은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인 및 과제는 무엇인가?
- 세계의 흡입 일산화질소 시장의 구조 및 주요 기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위 및 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서문
제5장 세계의 흡입 일산화질소 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 용도별
- 신생아 호흡기 치료
- 만성 폐색성 폐질환(COPD)
- 급성 호흡 곤란 증후군(ARDS)
- 기타
제7장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제8장 SWOT 분석
제9장 밸류체인 분석
제10장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제11장 가격 분석
제12장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Air Liquide SA
- Bellerophon Therapeutics
- Beyond Air Inc.
- Linde plc
- Mallinckrodt plc
- Merck KGaA
- Novoteris LLC
- Nu-Med Plus
- VERO Biotech LLC
AJY
The global inhaled nitric oxide market size reached US$ 943.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,657.7 Million by 2032, exhibiting a growth rate (CAGR) of 6.3% during 2024-2032.
Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
Inhaled Nitric Oxide Market Trends:
The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS. Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application.
Breakup by Application:
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease (COPD)
Acute Respiratory Distress Syndrome (ARDS)
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.
Key Questions Answered in This Report:
- How has the global inhaled nitric oxide market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global inhaled nitric oxide market?
- What are the key regional markets?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global inhaled nitric oxide market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Inhaled Nitric Oxide Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Application
- 6.1 Neonatal Respiratory Treatment
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Chronic Obstructive Pulmonary Disease (COPD)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Acute Respiratory Distress Syndrome (ARDS)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Region
- 7.1 North America
- 7.1.1 United States
- 7.1.1.1 Market Trends
- 7.1.1.2 Market Forecast
- 7.1.2 Canada
- 7.1.2.1 Market Trends
- 7.1.2.2 Market Forecast
- 7.2 Asia-Pacific
- 7.2.1 China
- 7.2.1.1 Market Trends
- 7.2.1.2 Market Forecast
- 7.2.2 Japan
- 7.2.2.1 Market Trends
- 7.2.2.2 Market Forecast
- 7.2.3 India
- 7.2.3.1 Market Trends
- 7.2.3.2 Market Forecast
- 7.2.4 South Korea
- 7.2.4.1 Market Trends
- 7.2.4.2 Market Forecast
- 7.2.5 Australia
- 7.2.5.1 Market Trends
- 7.2.5.2 Market Forecast
- 7.2.6 Indonesia
- 7.2.6.1 Market Trends
- 7.2.6.2 Market Forecast
- 7.2.7 Others
- 7.2.7.1 Market Trends
- 7.2.7.2 Market Forecast
- 7.3 Europe
- 7.3.1 Germany
- 7.3.1.1 Market Trends
- 7.3.1.2 Market Forecast
- 7.3.2 France
- 7.3.2.1 Market Trends
- 7.3.2.2 Market Forecast
- 7.3.3 United Kingdom
- 7.3.3.1 Market Trends
- 7.3.3.2 Market Forecast
- 7.3.4 Italy
- 7.3.4.1 Market Trends
- 7.3.4.2 Market Forecast
- 7.3.5 Spain
- 7.3.5.1 Market Trends
- 7.3.5.2 Market Forecast
- 7.3.6 Russia
- 7.3.6.1 Market Trends
- 7.3.6.2 Market Forecast
- 7.3.7 Others
- 7.3.7.1 Market Trends
- 7.3.7.2 Market Forecast
- 7.4 Latin America
- 7.4.1 Brazil
- 7.4.1.1 Market Trends
- 7.4.1.2 Market Forecast
- 7.4.2 Mexico
- 7.4.2.1 Market Trends
- 7.4.2.2 Market Forecast
- 7.4.3 Others
- 7.4.3.1 Market Trends
- 7.4.3.2 Market Forecast
- 7.5 Middle East and Africa
- 7.5.1 Market Trends
- 7.5.2 Market Breakup by Country
- 7.5.3 Market Forecast
8 SWOT Analysis
- 8.1 Overview
- 8.2 Strengths
- 8.3 Weaknesses
- 8.4 Opportunities
- 8.5 Threats
9 Value Chain Analysis
10 Porters Five Forces Analysis
- 10.1 Overview
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Degree of Competition
- 10.5 Threat of New Entrants
- 10.6 Threat of Substitutes
11 Price Analysis
12 Competitive Landscape
- 12.1 Market Structure
- 12.2 Key Players
- 12.3 Profiles of Key Players
- 12.3.1 Air Liquide S.A
- 12.3.1.1 Company Overview
- 12.3.1.2 Product Portfolio
- 12.3.1.3 Financials
- 12.3.1.4 SWOT Analysis
- 12.3.2 Bellerophon Therapeutics
- 12.3.2.1 Company Overview
- 12.3.2.2 Product Portfolio
- 12.3.2.3 Financials
- 12.3.3 Beyond Air Inc.
- 12.3.3.1 Company Overview
- 12.3.3.2 Product Portfolio
- 12.3.3.3 Financials
- 12.3.4 Linde plc
- 12.3.4.1 Company Overview
- 12.3.4.2 Product Portfolio
- 12.3.4.3 Financials
- 12.3.5 Mallinckrodt plc
- 12.3.5.1 Company Overview
- 12.3.5.2 Product Portfolio
- 12.3.5.3 Financials
- 12.3.6 Merck KGaA
- 12.3.6.1 Company Overview
- 12.3.6.2 Product Portfolio
- 12.3.6.3 Financials
- 12.3.6.4 SWOT Analysis
- 12.3.7 Novoteris LLC
- 12.3.7.1 Company Overview
- 12.3.7.2 Product Portfolio
- 12.3.8 Nu-Med Plus
- 12.3.8.1 Company Overview
- 12.3.8.2 Product Portfolio
- 12.3.8.3 Financials
- 12.3.9 VERO Biotech LLC
- 12.3.9.1 Company Overview
- 12.3.9.2 Product Portfolio
